Hospira Inc Pharmaceutical Import Profile — United States (DGFT 2022–2026)

Name: Hospira Inc Pharmaceutical Import Records from India — 2 Products, $1.4M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Hospira Inc — Pharmaceutical Importer Profile (2026) | 2 Products, $1.4M Trade | TransData Nexus

Hospira Inc

Pharmaceutical Importer · United States · Cardiovascular Focus · $1.4M Total Trade · DGFT Verified

Hospira Inc is a pharmaceutical importer based in United States with a total trade value of $1.4M across 2 products in 2 therapeutic categories. Based on 27 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Hospira Inc sources from 3 verified Indian suppliers, with Gland Pharma Limited accounting for 70.4% of imports.

Hospira Inc — Import Portfolio & Supplier Network

Hospira Inc import network — 2 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Hospira Inc?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Gland Pharma Limited	$21.3M	482	70.4%
Pfizer Healthcare India Private Limited	$8.9M	186	29.3%
Zydus Hospira Oncology Private Limited

What Formulations Does Hospira Inc Import?

Formulation	Value	Ships
Levetiracetam injection 500MG/5ML (100MG	$3.8M	93
Milrinone lactate injection 1MG/ML, 50ML	$1.9M	48
Levetiracetam injection 500MG/5ML (100MG/ML)	$1.8M	39
Bupivac 0.5 percent 30ML ssol 1x25	$1.5M	32
Propofol USP 1g/100ML emulsion 1x10	$1.3M	27
Rocuronium bromide injection 10MG/ML 5ML	$1.3M	27
Rocuronium bromide injection 10MG/ML, 5ML	$1.0M	21
Milrinone lactate in 5 percent	$848.7K	17
Levetiracetam injection 500MG/5ML 100MG/ML	$757.6K	17
Heparin 30000u/30ML ssol 1x25	$750.0K	15
Rocuronium bromide injection 10MG/ML 10ML	$700.0K	14
Rocuronium bromide injection 10MG/ML, 5ML	$648.9K	14
Milrinone lactate injection 1MG/ML	$594.0K	15
Levetiracetam injection 500MG 5ML 100MG ML	$580.9K	13
Lidocaine hcl INJ 1 percent ssol 25x50ml	$520.6K	11

Hospira Inc imports 109 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 2 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Heparin	Cardiovascular	$950.0K	19	0.3%	5
2	Furosemide	Diuretics	$400.0K	8	0.6%	6

Hospira Inc imports 2 pharmaceutical products across 2 categories into United States totaling $1.4M.

Hospira Inc — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Hospira Inc., headquartered in Lake Forest, Illinois, was a leading American pharmaceutical and medical device company specializing in injectable drugs and infusion technologies. Established on May 3, 2004, following its spin-off from Abbott Laboratories, Hospira's portfolio encompassed generic acute-care and oncology injectables, as well as integrated infusion therapy and medication management systems. These products were primarily utilized by hospitals and alternate site providers, including clinics, home healthcare providers, and long-term care facilities.

In September 2015, Hospira was acquired by Pfizer Inc., a global leader in the pharmaceutical industry. This acquisition aimed to enhance Pfizer's Global Established Pharmaceutical (GEP) business by integrating Hospira's expertise in injectable drugs and biosimilars. Following the acquisition, Hospira's operations were incorporated into Pfizer's broader pharmaceutical distribution network, contributing to the company's extensive reach in the United States and internationally.

2Distribution Network

Prior to its acquisition, Hospira maintained a robust distribution network across the United States, with operations in multiple states to support its extensive product portfolio. The company's logistics capabilities included a combination of centralized and regional distribution centers, ensuring efficient delivery of products to hospitals and healthcare providers nationwide. While specific warehouse locations and geographic coverage details are not publicly disclosed, Hospira's integration into Pfizer's distribution infrastructure has likely expanded its reach and enhanced logistical efficiency.

3Industry Role

Before its acquisition by Pfizer, Hospira Inc. played a significant role in the United States pharmaceutical supply chain as a primary wholesaler and supplier of injectable pharmaceuticals. The company's focus on generic acute-care and oncology injectables positioned it as a key provider to hospitals and healthcare facilities, contributing to the availability of essential medications in the acute-care sector. Following the acquisition, Hospira's operations have been integrated into Pfizer's broader distribution network, continuing to serve as a critical supplier of injectable drugs and biosimilars within the U.S. market.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Hospira Inc

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Hospira's sourcing strategy involved a diversified supplier base, with significant imports from India. Between 2022 and 2026, the company imported finished pharmaceutical formulations totaling $1.4 million USD across 27 shipments, encompassing 109 unique formulations. The top five products imported from India included Heparin ($950K) and Furosemide ($400K), accounting for 0.3% and 0.6% of the total import value, respectively. The primary suppliers were GLAND PHARMA LIMITED ($21.3M, 70.4% of shipments) and PFIZER HEALTHCARE INDIA PRIVATE LIMITED ($8.9M, 29.3% of shipments), indicating a strong reliance on these suppliers for the majority of imported products.

This sourcing concentration suggests a strategic choice to maintain consistent product quality and supply chain stability. The substantial volume of imports from these suppliers indicates a well-established relationship, likely characterized by favorable terms and reliable delivery schedules. However, the lack of a diversified supplier base could pose risks related to supply chain disruptions or changes in supplier dynamics.

2Supply Chain Resilience

The resilience of Hospira's Indian supply chain appears to be robust, given the substantial volume of imports from GLAND PHARMA LIMITED and PFIZER HEALTHCARE INDIA PRIVATE LIMITED. The importation of 109 unique formulations indicates a diverse product range, which can mitigate risks associated with dependency on a single product line. However, the concentration of imports from two primary suppliers suggests limited backup options in the event of supply chain disruptions.

Importing Pharmaceuticals into United States — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for United States

1Regulatory Authority & Framework

In the United States, the Food and Drug Administration (FDA) serves as the primary regulatory authority overseeing the importation, manufacturing, and distribution of pharmaceutical products. The FDA enforces the Federal Food, Drug, and Cosmetic Act, which sets forth the legal framework for drug approval, labeling, and quality standards. Pharmaceutical imports must comply with FDA regulations to ensure the safety, efficacy, and quality of drugs available in the U.S. market.

The marketing authorization pathway for Indian generics involves several key steps:

1. Abbreviated New Drug Application (ANDA): Indian manufacturers must submit an ANDA to the FDA, demonstrating that their generic product is bioequivalent to the reference listed drug.

2. Good Manufacturing Practice (GMP) Compliance: Manufacturers must adhere to FDA's GMP regulations, ensuring that products are consistently produced and controlled to quality standards.

3. FDA Inspection: The FDA conducts inspections of manufacturing facilities to verify compliance with GMP and other regulatory requirements.

4. Approval and Importation: Upon successful evaluation, the FDA grants approval, allowing the product to be imported and marketed in the U.S.

2Import Licensing & GMP

Import licensing requirements for pharmaceutical products in the United States are governed by the FDA. Indian exporters must obtain FDA approval for each product they intend to export, which involves submitting an ANDA and ensuring compliance with FDA regulations. Additionally, Indian manufacturers must hold a valid GMP certificate recognized by the FDA, demonstrating adherence to quality manufacturing practices.

Hospira Inc — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Hospira's focus on importing finished pharmaceutical formulations from India, particularly in the therapeutic categories of cardiovascular and diuretics, aligns with the company's strategic emphasis on providing essential medications for acute-care settings. The importation of Heparin and Furosemide, both critical in managing cardiovascular conditions and fluid balance, reflects market demand for cost-effective, high-quality generic alternatives to branded drugs.

The substantial import value of these products indicates a strong market demand and Hospira's commitment to meeting the needs of healthcare providers and patients. By sourcing these formulations from India, Hospira leverages the country's manufacturing capabilities and cost advantages, contributing to the affordability and accessibility of essential medications in the U.S. market.

2Sourcing Profile

Hospira's sourcing strategy for generic drugs involves importing finished pharmaceutical formulations from India, focusing on products that are critical in acute-care settings. The company's preference for sourcing from India is driven by the country's established pharmaceutical manufacturing industry, which offers a wide range of high-quality, cost-effective generic medications. This approach allows Hospira to provide essential drugs to the U.S. market while maintaining competitive pricing and ensuring a reliable supply chain.

Market Positioning

Frequently Asked Questions — Hospira Inc

What products does Hospira Inc import from India?

Hospira Inc imports 2 pharmaceutical products across 2 categories. Top imports: Heparin ($950.0K), Furosemide ($400.0K).

Who supplies pharmaceuticals to Hospira Inc from India?

Hospira Inc sources from 3 verified Indian suppliers. The primary supplier is Gland Pharma Limited (70.4% of imports, $21.3M).

What is Hospira Inc's total pharmaceutical import value?

Hospira Inc's total pharmaceutical import value from India is $1.4M, based on 27 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Hospira Inc focus on?

Hospira Inc imports across 2 categories. The largest: Cardiovascular (70.4%), Diuretics (29.6%).

Get Full Hospira Inc Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.